Remission rates. Remission rates shown for patients in the efficacy analysis set who were treated with CPX-351 plus venetoclax (arm A) or CPX-351 plus midostaurin (arm B); n represents the number of patients who achieved a best response of CR, CRi, or CRh; N, the number of patients who received ≥1 dose of study drug and had an evaluable BM result.